CALA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CALA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Calithera Biosciences's change in receivables for the quarter that ended in Dec. 2022 was $0.00 Mil. It means Calithera Biosciences's Accounts Receivable stayed the same from Sep. 2022 to Dec. 2022 .
Calithera Biosciences's change in receivables for the fiscal year that ended in Dec. 2022 was $0.00 Mil. It means Calithera Biosciences's Accounts Receivable stayed the same from Dec. 2021 to Dec. 2022 .
Calithera Biosciences's Accounts Receivable for the quarter that ended in Dec. 2022 was $0.00 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Calithera Biosciences's liquidation value for the three months ended in Dec. 2022 was $17.17 Mil.
The historical data trend for Calithera Biosciences's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Calithera Biosciences Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Change In Receivables | Get a 7-Day Free Trial | -0.86 | 1.52 | -1.06 | 1.54 | - |
Calithera Biosciences Quarterly Data | ||||||||||||||||||||
Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | |
Change In Receivables | Get a 7-Day Free Trial | 0.01 | -0.13 | 0.13 | - | - |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Calithera Biosciences (OTCPK:CALA) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Calithera Biosciences's Days Sales Outstanding for the quarter that ended in Dec. 2022 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 0 | / | 0 | * | 91 |
= |
2. In Ben Graham's calculation of liquidation value, Calithera Biosciences's accounts receivable are only considered to be worth 75% of book value:
Calithera Biosciences's liquidation value for the quarter that ended in Dec. 2022 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 25.451 | - | 8.284 | + | 0.75 * 0 | + | 0.5 * 0 |
= | 17.17 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Calithera Biosciences's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Deepika Pakianathan | director, 10 percent owner | 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402 |
Takeda Ventures, Inc. | 10 percent owner | 9625 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121 |
Keith Orford | officer: SR. VP, CLINICAL DEVELOPMENT | CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SOUTH SAN FRANCISCO CA 94080 |
Jonathan G Drachman | director | 21823 30TH DRIVE SE, BOTHELL WA 98021 |
Susan Molineaux | director, officer: PRESIDENT AND CEO | C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD., SUITE 200, SOUTH SAN FRANCISCO CA 94080 |
Christopher Molineaux | officer: SR. VP, DEVELOPMENT | CALITHERA BIOSCIENCES, 343 OYSTER POINT, SUITE 200, SOUTH SAN FRANCISCO CA 94080 |
Emil Kuriakose | officer: CHIEF MEDICAL OFFICER | 343 OYSTER POINT BLVD, SUITE 200, SOUTH SAN FRANCISCO CA 94080 |
Millennium Pharmaceuticals Inc | 10 percent owner | 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Takeda Pharmaceutical Co Ltd | 10 percent owner | 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668 |
J. Scott Garland | director | 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
Biotechnology Value Fund L P | other: See Explanation of Responses | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Stephanie Wong | officer: VP, FINANCE | 343 OYSTER POINT BLVD #200, SOUTH SAN FRANCISCO CA 94080 |
Bvf Inc/il | 10 percent owner | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Biotechnology Value Fund Ii Lp | other: See Explanation of Responses | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Mark N Lampert | 10 percent owner | 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 05-20-2022
By GuruFocusNews GuruFocusNews • 06-26-2022
By GuruFocusNews GuruFocusNews • 07-06-2022
By GuruFocusNews GuruFocusNews • 06-24-2022
By PurpleRose PurpleRose • 08-08-2022
By Value_Insider Value_Insider • 11-14-2022
By GuruFocus Research GuruFocus Editor • 02-13-2023
By GuruFocusNews GuruFocusNews • 06-19-2022
By GuruFocusNews GuruFocusNews • 05-27-2022
By GuruFocusNews GuruFocusNews • 07-04-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.